Search results for "carriers"

showing 10 items of 391 documents

Extracellular vesicles and high‐density lipoproteins: Exercise and oestrogen‐responsive small RNA carriers

2023

Decreased systemic oestrogen levels (i.e., menopause) affect metabolic health. However, the detailed mechanisms underlying this process remain unclear. Both oestrogens and exercise have been shown to improve metabolic health, which may be partly mediated by circulating microRNA (c-miR) signalling. In recent years, extracellular vesicles (EV) have increased interest in the field of tissue crosstalk. However, in many studies on EV-carried miRs, the co-isolation of high-density lipoprotein (HDL) particles with EVs has not been considered, potentially affecting the results. Here, we demonstrate that EV and HDL particles have distinct small RNA (sRNA) content, including both host and nonhost sRN…

estrogeenitextracellular RNA-carriershormonal therapyHistologyvaihdevuodetkuntoliikuntaphysical activityCell Biologyregulatory RNAacute exercisepostmenopausepeakoxygen uptakehormonihoitotasannevuodetoestrogen deficiencymetabolismaineenvaihduntafyysinen aktiivisuusJournal of Extracellular Vesicles
researchProduct

Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch r…

2022

Abstract Objective To compare colorectal cancer (CRC) incidences in carriers of pathogenic variants of the MMR genes in the PLSD and IMRC cohorts, of which only the former included mandatory colonoscopy surveillance for all participants. Methods CRC incidences were calculated in an intervention group comprising a cohort of confirmed carriers of pathogenic or likely pathogenic variants in mismatch repair genes (path_MMR) followed prospectively by the Prospective Lynch Syndrome Database (PLSD). All had colonoscopy surveillance, with polypectomy when polyps were identified. Comparison was made with a retrospective cohort reported by the International Mismatch Repair Consortium (IMRC). This com…

koloskopiaEuropean Hereditary Tumour Group (EHTG) and the International Mismatch Repair Consortium (IMRC)Epidemiology3122 Cancersehkäisycolorectal cancerPenetrancesegregaatioläpäisevyyssuolistosyövätGUIDELINESover-diagnosisSDG 3 - Good Health and Well-beingpreventionTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]1112 Oncology and CarcinogenesisOncology & CarcinogenesispenetranceLynchin oireyhtymäEpidemiologiaSegregation analysisOver-diagnosiGenetics (clinical)segregation analysisScience & TechnologyIncidencePreventionColonoscòpiaGERMLINE MUTATIONSColonoscopyprospectiveCARRIERSColorectal cancer3142 Public health care science environmental and occupational healthProspectiveLynch syndromeOncologyLynch SyndromeOver-diagnosisincidence/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingCLINICAL MANAGEMENTilmaantuvuusLife Sciences & Biomedicine
researchProduct

Extracellular Vesicles as Biological Shuttles for Targeted Therapies.

2019

The development of effective nanosystems for drug delivery represents a key challenge for the improvement of most current anticancer therapies. Recent progress in the understanding of structure and function of extracellular vesicles (EVs)—specialized membrane-bound nanocarriers for intercellular communication—suggests that they might also serve as optimal delivery systems of therapeutics. In addition to carrying proteins, lipids, DNA and different forms of RNAs, EVs can be engineered to deliver specific bioactive molecules to target cells. Exploitation of their molecular composition and physical properties, together with improvement in bio-techniques to modify their content are critical iss…

liposomesMolecular compositionBioactive moleculesReviewExtracellular vesiclesCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciencesExtracellular Vesicles0302 clinical medicineDrug Delivery SystemsPlant-derived extracellular vesicleAnimalsHumanstarget therapiesTarget therapyPhysical and Theoretical ChemistryRNA Small Interferinglcsh:QH301-705.5Molecular BiologySpectroscopy030304 developmental biology0303 health sciencesDrug CarriersChemistryOrganic ChemistryGeneral MedicinePlantsComputer Science ApplicationsStructure and functionCell biologyLiposomeplant-derived extracellular vesicleslcsh:Biology (General)lcsh:QD1-999Pharmaceutical Preparations030220 oncology & carcinogenesisDrug deliverydrug deliveryExtracellular vesicleNanocarriersDrug carrierInternational journal of molecular sciences
researchProduct

Mastering the Tools: Natural versus Artificial Vesicles in Nanomedicine

2020

Naturally occurring extracellular vesicles and artificially made vesicles represent important tools in nanomedicine for the efficient delivery of biomolecules and drugs. Since its first appearance in the literature 50 years ago, the research on vesicles is progressing at a fast pace, with the main goal of developing carriers able to protect cargoes from degradation, as well as to deliver them in a time- and space-controlled fashion. While natural occurring vesicles have the advantage of being fully compatible with their host, artificial vesicles can be easily synthetized and functionalized according to the target to reach. Research is striving to merge the advantages of natural and artifici…

liposomesolymersomesnanotherapeuticComputer scienceBiomedical EngineeringPharmaceutical SciencenanotherapeuticsNanotechnology02 engineering and technologyexosomes010402 general chemistry01 natural sciencesExtracellular vesiclesArtificial vesicleBiomaterialsexosomenanomaterialsSettore CHIM/02 - Chimica FisicaDrug CarriersVesicleBiological Transport021001 nanoscience & nanotechnologynanomedicineMicrovesicles0104 chemical sciencespolymersomesPolymersomeliposomeNanomedicinenanomaterialextracellular vesicleartificial vesicles0210 nano-technologyextracellular vesiclesMerge (version control)
researchProduct

Mesoporous Silica-Based Materials with Bactericidal Properties

2019

[EN] Bacterial infections are the main cause of chronic infections and even mortality. In fact, due to extensive use of antibiotics and, then, emergence of antibiotic resistance, treatment of such infections by conventional antibiotics has become a major concern worldwide. One of the promising strategies to treat infection diseases is the use of nanomaterials. Among them, mesoporous silica materials (MSMs) have attracted burgeoning attention due to high surface area, tunable pore/particle size, and easy surface functionalization. This review discusses how one can exploit capacities of MSMs to design and fabricate multifunctional/controllable drug delivery systems (DDSs) to combat bacterial …

medicine.drug_classAntibioticsNanotechnologyBiocompatible Materials02 engineering and technologyMicrobial Sensitivity Tests010402 general chemistryBacterial Physiological Phenomena01 natural sciencesantibioticsBiomaterialsAntibiotic resistanceDrug Delivery SystemsQUIMICA ORGANICAAntibioticsQUIMICA ANALITICAmedicineHigh surface areaHumansGeneral Materials ScienceControllable drug delivery systemsSettore CHIM/02 - Chimica FisicaDrug Carrierscontrollable drug delivery systemsBacteriaChemistryQUIMICA INORGANICABiofilmGeneral ChemistryMesoporous silica021001 nanoscience & nanotechnologyAntimicrobialSilicon Dioxide0104 chemical sciencesAnti-Bacterial AgentsNanostructuresmesoporous silica materialsBiofilmsDrug deliveryMesoporous silica materialsSurface modificationNanoparticlesnanoparticles0210 nano-technologyPorosityBiotechnology
researchProduct

Clinical Trial Results of Peginterferons in Combination with Ribavirin

2003

Of the large number of patients chronically infected with hepatitis C virus (HCV), only about one third have progressive liver disease, and will eventually develop cirrhosis and hepatocellular carcinoma. These are the patients for whom effective antiviral treatment is most needed. Therapy is currently recommended for patients with chronic hepatitis C who have abnormal alanine aminotransferase (ALT) levels, detectable hepatitis C virus ribonucleic acid (HCV RNA) in the blood, and significant necroinflammatory changes and/or fibrosis on liver biopsy. The current gold standard in terms of treatment efficacy is the combination of peginterferon (PEG-IFN) and ribavirin. The overall sustained viro…

medicine.medical_specialtyCirrhosisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolsantiviral agentchemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHumansClinical Trials as TopicDrug CarriersHepatologymedicine.diagnostic_testbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesTreatment OutcomechemistryLiver biopsyHepatocellular carcinomaImmunologyclinical trials hepatitis CDrug Therapy CombinationbusinessViral loadSeminars in Liver Disease
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo

2012

Abstract Introduction Bisphosphonates are important and effective drugs in oncology and osteoporosis therapy. They accumulate in the bone matrix becoming released and active by bone resorption. This leads to effective inhibition of tumor cells and bone degradation. A side effect of bisphosphonates similar to other drugs like denosumab is osteonecrosis of the jaws (ONJ). This problem mostly occurs after tooth extraction. We studied the cytoprotectant dexrazoxane known from anthracycline chemotherapy for cytoprotection in nitrogen-containing bisphosphonate treated cells and in the rabbit tibia model to evaluate a possible value in ONJ management. Materials & methods Human osteoblasts (HOB) P2…

medicine.medical_treatmentOsteoporosisCell Culture TechniquesGingivaTetrazolium SaltsApoptosisPharmacologyCell morphologyZoledronic AcidOsteogenesisColoring AgentsDrug CarriersBone Density Conservation AgentsDiphosphonatesImidazolesFluoresceinsResorptionDenosumabModels AnimalFemaleCollagenRabbitsOral SurgeryRazoxanemedicine.drugmedicine.medical_specialtyCell SurvivalProtective AgentsBone resorptionCell LinemedicineAnimalsHumansBone ResorptionCell ShapeFluorescent DyesOsteoblastsTibiabusiness.industryFibroblastsBisphosphonatemedicine.diseaseSurgeryThiazolesDurapatiteZoledronic acidOtorhinolaryngologyCytoprotectionSurgeryDexrazoxanebusinessJournal of Cranio-Maxillofacial Surgery
researchProduct

Descriptive study on subjective experience of genetic testing with respect to relationship, family planning and psychosocial wellbeing among women wi…

2021

AbstractBackgroundDue to increased risk of endometrial and ovarian cancer, women belonging to known Lynch Syndrome (LS) families are recommended to undergo germline testing. Current practice in Finland is to offer counselling to women with pathogenic variant and advocate risk-reducing surgery (RRS) after completion of childbirth. The present study aimed to clarify the impacts of positive germline testing on family planning and reproductive decisions of these women, which are relatively unknown.MethodsSeventy-nine carriers of germline MMR gene pathogenic variant (path_MMR)were identified from the Finnish LS Registry as having genetic testing performed before the age of 45 years and not havin…

medicine.medical_treatmentTestingQH426-470ihmissuhteetCOLORECTAL-CANCER0302 clinical medicinehenkinen hyvinvointi5. Gender equality3123 Gynaecology and paediatricsChildbirthGenetics (clinical)RC254-282media_common0303 health sciencesmedicine.diagnostic_test030305 genetics & heredityNeoplasms. Tumors. Oncology. Including cancer and carcinogensLynch syndrometesting3. Good healthOncologyhereditary cancerFamily planning030220 oncology & carcinogenesissyöpätauditPsychosocialClinical psychologymedia_common.quotation_subject3122 CancersFertilityMUTATION CARRIERSPsychosocial wellbeingtestaus03 medical and health sciencesCHILDBEARINGmedicineGeneticsFERTILITYLynchin oireyhtymäGenetic testingperinnölliset tauditbusiness.industryEndometrial cancerResearchOophorectomyENDOMETRIAL CANCERmedicine.diseaseHereditary cancerperhesuunnitteluLynch syndromerelationshipsRelationshipsbusinesspsychosocial wellbeing
researchProduct

Excitation Transfer Engineering in Ce-Doped Oxide Crystalline Scintillators by Codoping with Alkali-Earth Ions

2018

This work has been supported by the European Social Fund Measure No. 09.3.3-LMT-K-712 activity Improvement of Researchers Qualification by Implementing the World-Class R&D Projects, and by grant #14.W03.31.0004 of the Russian Federation Government. Authors are grateful to CERN Crystal Clear Collaboration and COST Action TD1401 "Fast Advanced Scintillator Timing (FAST)" for support of collaboration.

multicomponent garnetsMaterials scienceInorganic chemistryexcitation transferscintillators02 engineering and technologyScintillator7. Clean energy01 natural sciencesDoped oxideIonfree carrier0103 physical sciences:NATURAL SCIENCES:Physics [Research Subject Categories]Materials ChemistryElectrical and Electronic EngineeringAlkaline earth metal010308 nuclear & particles physicsmulticomponent garnetfree carriersSurfaces and Interfaces021001 nanoscience & nanotechnologyCondensed Matter PhysicsFree carrierSurfaces Coatings and FilmsElectronic Optical and Magnetic Materialsscintillator0210 nano-technologyExcitationphysica status solidi (a)
researchProduct